Olaparib, a new hope for ovarian cancer

被引：0
|
作者：
Samoon, Zarka [1 ]
Jabbar, Adnan Abdul [1 ]
机构：
[1] Aga Khan Univ Hosp, Dept Oncol, Karachi, Pakistan
来源：
INDIAN JOURNAL OF CANCER | 2020年 / 57卷 / 03期
关键词：
MAINTENANCE THERAPY; PHASE-2; PARP;
D O I：
10.4103/ijc.IJC_1_19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：346 / 347
页数：2
相关论文
共 50 条
  • [31] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    Liu, Joyce F.
    Barry, William T.
    Birrer, Michael
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Whalen, Christin
    Obermayer, Lisa
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    LANCET ONCOLOGY, 2014, 15 (11) : 1207 - 1214
  • [32] Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
    Zheng, Hong
    Gao, Yunong
    Guo, Hongyan
    Li Li
    Li, Qingshui
    Cui, Heng
    Lin, An
    Sun, Lixin
    Hu, Yuanjing
    Kang, Shan
    Duan, Wei
    Pan, Lingya
    Wang, Shuzhen
    Yang, Yingjie
    Li, Yunxia
    Kong, Weimin
    Xiang, Yang
    Tian, Xiaofei
    Ling, Bin
    Ha, Chunfang
    Bai, Wenpei
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (09) : 1735 - 1742
  • [33] Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
    Gralewska, Patrycja
    Gajek, Arkadiusz
    Marczak, Agnieszka
    Rogalska, Aneta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [34] Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
    Lorusso, Domenica
    Tripodi, Elisa
    Maltese, Giuseppa
    Lepori, Stefano
    Sabatucci, Ilaria
    Bogani, Giorgio
    Raspagliesi, Francesco
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1501 - 1509
  • [35] FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
    Miao, Huixian
    Meng, Huangyang
    Zhang, Yashuang
    Chen, Tian
    Zhang, Lin
    Cheng, Wenjun
    CELL DEATH AND DIFFERENTIATION, 2024, 31 (04) : 497 - 510
  • [36] Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
    Tang, Sangsang
    Shen, Yuanming
    Wei, Xinyi
    Shen, Zhangjin
    Lu, Weiguo
    Xu, Junfen
    CELL DEATH & DISEASE, 2022, 13 (09)
  • [37] Body composition and inflammation variables as the potential prognostic factors in epithelial ovarian cancer treated with Olaparib
    Guo, Xingzi
    Tang, Jie
    He, Haifeng
    Jian, Lian
    Qiang, Ouyang
    Xie, Yongzhi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] New treatments in ovarian cancer
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28 : 57 - 60
  • [39] New Therapies for Ovarian Cancer
    Armstrong, Deborah K.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 632 - 635
  • [40] Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
    Barnicle, Alan
    Ray-Coquard, Isabelle
    Rouleau, Etienne
    Cadoo, Karen
    Simpkins, Fiona
    Aghajanian, Carol
    Leary, Alexandra
    Poveda, Andres
    Lheureux, Stephanie
    Pujade-Lauraine, Eric
    You, Benoit
    Ledermann, Jonathan
    Matulonis, Ursula
    Gourley, Charlie
    Timms, Kirsten M.
    Lai, Zhongwu
    Hodgson, Darren R.
    Elks, Cathy E.
    Dearden, Simon
    Egile, Coumaran
    Lao-Sirieix, Pierre
    Harrington, Elizabeth A.
    Brown, Jessica S.
    GENOME MEDICINE, 2024, 16 (01): : 145
12345